SYRS | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

-60.00%

6 Months

-90.91%

1 Year

-99.29%

2 Year

-99.29%

Key data

Stock price

$0.00

P/E Ratio

N/A

DAY RANGE

$0.00 - $0.00

EPS

N/A

52 WEEK RANGE

$0.00 - $0.04

52 WEEK CHANGE

-$99.29

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$26,513

AVERAGE 30 VOLUME

$33,658

Company detail

CEO: Nancy A. Simonian
Region: US
Website: syros.com
Employees: 120
IPO year: 2016

Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.

SYRS - Syros Pharmaceuticals, Inc.